In GPIIb/IIIa mediated arterial thrombosis platelet activation plays a central role. To discover platelet activation inhibitor the pharmacophores of GPIIb/IIIa receptor inhibitors and anti-thrombotic agents were analyzed. This led to the design of (1R,3S)- and (1S,3S)-1-methyl-1,2,3,4-tetrahydro-β-carboline-3-carboxylic acids as GPIIb/IIIa inhibitors. Comparing to (1S,3S)-isomer (1R,3S)-isomer had
在G
PIIb / IIIa介导的动脉血栓形成中,血小板活化起着核心作用。为了发现血小板活化
抑制剂,分析了G
PIIb / IIIa受体
抑制剂和抗血栓形成剂的药效团。这导致设计了(1 R,3 S)-和(1 S,3 S)-1-甲基-1,2,3,4-四氢-β-咔啉-3-
羧酸作为G
PIIb / IIIa
抑制剂。与(1 S,3 S)-异构体相比(1 R,3 S)-异构体具有较低的cdocker相互作用能。A
FM图像显示(1 S,3 S)-异构体和(1 R,3 S)-异构体抑制血小板活化分别为10 -5 M和10 -6M 。体内1μmol/ kg口服(1 S,3 S)异构体可有效抑制大鼠形成动脉血栓并下调G
PIIb / IIIa表达,但活性明显低于1μmol/ kg口服(1 S,3 S)异构体(1 R,3S)-异构体。(1 S,3 S)-异构体和(1 R,3 S)-异构体均可安全用于结构修饰,但(1